FrancophonIA/ELRC3.0 huggingface dataset:
English: In this analysis, AUC was estimated to be 5.82%, 10.4%, and 17.3% lower in subjects with BMI of 30, 35, and 45 kg/m2, respectively, compared to subjects with a body mass index of 25 kg/m2.
Slovenian: 10,4 % oz. 17,3 % nižja pri osebah z ITM 30, 35 oz. 45 kg/m2 v primerjavi z osebami z indeksom telesne mase 25 kg/m2.
English: An embryofetal development study in pregnant rats did not indicate a teratogenic effect attributed to the co-administration of empagliflozin and metformin at exposures of approximately 14-times the clinical AUC exposure of empagliflozin associated with the highest dose, and 4-times the clinical AUC exposure of metformin associated with the 2000 mg dose.
Slovenian: Študija o učinkih na razvoj zarodka in plodu pri brejih podganah ni pokazala teratogenih učinkov sočasnega dajanja empagliflozina in metformina pri izpostavljenostih, ki so bile približno 14-krat večje od klinične izpostavljenosti empagliflozinu na podlagi vrednosti AUC, ki je povezana z največjim odmerkom, in 4-krat večje od klinične izpostavljenosti metforminu na podlagi vrednosti
English: In vitro studies suggested that the primary route of metabolism of empagliflozin in humans is glucuronidation by the uridine 5'-diphospho-glucuronosyltransferases UGT2B7, UGT1A3, UGT1A8, and UGT1A9.
Slovenian: Podatki in vitro kažejo, da je glavna presnovna pot empagliflozina pri ljudeh glukuronidacija z uridin 5‘-difosfo-glukuronoziltransferazami UGT1A3, UGT1A8, UGT1A9 in UGT2B7.
English: Due to the metformin component, co-administration of anaesthesia can increase the risk of side effects.
Slovenian: Zaradi metformina lahko sočasno dajanje anestezije poveča tveganje neželenih učinkov.
English: Metformin is excreted into human milk.
Slovenian: Dojenje Metformin se izloča v materino mleko.
English: Table 6 Efficacy results at 12 week in a placebo-controlled study of empagliflozin in patients with type 2 diabetes and uncontrolled blood pressurea
Slovenian: Preglednica 6: Rezultati učinkovitosti v 12. tednu v s placebom nadzorovani študiji empagliflozina pri bolnikih s sladkorno boleznijo tipa 2 in nekontroliranim krvnim tlakoma placebo empagliflozin
English: In a prospective, pre-specified meta-analysis of independently adjudicated cardiovascular events from 12 phase 2 and 3 clinical studies involving 10,036 patients with type 2 diabetes, empagliflozin did not increase cardiovascular risk.
Slovenian: 12 kliničnih študijah 2. in 3. faze, ki so zajele 10.036 bolnikov s sladkorno boleznijo tipa 2,
English: 2 Identified adverse reactions of empagliflozin monotherapy 3 Identified adverse reactions of metformin monotherapy 4 Long-term treatment with metformin has been associated with a decrease in vitamin B12 absorption which may very rarely result in clinically significant vitamin B12 deficiency (e.g. megaloblastic anaemia)
Slovenian: 4 Dolgotrajno zdravljenje z metforminom so povezali z zmanjšano absorpcijo vitamina B12, kar lahko zelo redko pripelje do klinično pomembnega pomanjkanja tega vitamina (npr. megaloblastne anemije).
English: Empagliflozin 24 months data, as add-on to metformin in comparison to glimepiride In a study comparing the efficacy and safety of empagliflozin 25 mg versus glimepiride (up to 4 mg per day) in patients with inadequate glycaemic control on metformin alone, treatment with empagliflozin daily resulted in superior reduction in HbA1c (Table 3), and a clinically meaningful reduction in FPG, compared to glimepiride.
Slovenian: V študiji, v kateri so primerjali učinkovitost in varnost empagliflozina 25 mg z glimepiridom (do 4 mg na dan) pri bolnikih z neustrezno urejeno glikemijo, ki so dobivali samo metformin, je dnevno zdravljenje z empagliflozinom povzročilo večje zmanjšanje vrednosti HbA1c (preglednica 3), in klinično pomembno zmanjšanje vrednosti FPG, v primerjavi z gimepiridom.
English: A total of 4704 patients with type 2 diabetes were treated in 7 double-blind, placebo or active-controlled clinical studies of at least 24 weeks duration, of which 1109 patients received empagliflozin 10 mg and 1863 received empagliflozin 25 mg as add-on to metformin therapy.
Slovenian: Klinična učinkovitost in varnost V 7 dvojno slepih, s placebom ali zdravilno učinkovino nadzorovanih kliničnih študijah, je bilo zdravljenih skupaj 4.704 bolnikov s sladkorno boleznijo tipa 2 najmanj 24 tednov, od tega jih je 1.109 prejemalo empagliflozin 10 mg in 1.863 empagliflozin 25 mg kot dodatno zdravljenje k metforminu.
English: Table 4: Efficacy results at 18 and 52 weeks in a placebo-controlled study of empagliflozin as add-on to multiple daily doses of insulin with concomitant metformin therapy
Slovenian: Preglednica 4: Rezultati učinkovitosti v 18. in 52. tednu v s placebom nadzorovani študiji z empagliflozinom kot dodatnim zdravljenjem k večkratnim dnevnim odmerkom insulina sočasno z metforminom placebo empagliflozin
English: A greater proportion of patients treated with empagliflozin and with a baseline HbA1c ≥7.0% achieved a target HbA1c of <7% compared to placebo (Table 5).
Slovenian: V primerjavi s placebom je večji delež bolnikov, zdravljenih z empagliflozinom in z izhodiščno vrednostjo HbA1c ≥ 7,0 %, dosegel ciljno vrednost HbA1c < 7 % (preglednica 5).
English: Special caution should be exercised in situations where renal function may become impaired, for example in case of dehydration, or when initiating antihypertensive therapy or diuretic therapy and when starting therapy with a non-steroidal anti-inflammatory drug (NSAID).
Slovenian: Posebna previdnost je potrebna v razmerah, ko bi lahko prišlo do okvare v delovanju ledvic, na primer v primeru dehidracije ali na začetku zdravljenja z antihipertenzivom, diuretikom ali nesteroidnim protivnetnim zdravilom
English: An urge to pass urine or more frequent urination may be due to the way Synjardy works, but as they can also be signs of urinary tract infection.
Slovenian: • bolečina v predelu medenice ali sredine hrbta (če so okužene ledvice) Nuja po uriniranju ali pogostejše uriniranje sta lahko posledica načina delovanja zdravila Synjardy, vendar sta lahko tudi znak okužbe sečil, zato se morate z zdravnikom posvetovati tudi, če se število teh simptomov poveča.
English: • feeling sick (nausea), vomiting
Slovenian: Zelo pogosti • občutek slabosti (navzea), bruhanje
English: A total of 7052 patients with type 2 diabetes were treated in clinical studies to evaluate the safety of empagliflozin as add-on to metformin, of which 4740 patients were treated with empagliflozin as add-on to metformin.
Slovenian: V klinične študije za ocenitev varnosti empagliflozina kot dodatnega zdravljenja k metforminu je bilo vključenih skupaj 7.052 bolnikov s sladkorno boleznijo tipa 2, od katerih se je 4.740 zdravilo z empagliflozinom kot dodatnim zdravljenjem k metforminu.
English: Stop taking this medicine immediately and contact a doctor or the nearest hospital straight away.
Slovenian: Takoj prenehajte jemati to zdravilo in se obrnite na zdravnika ali takoj pojdite v bolnišnico.
English: * p-value <0.0001 ** p-value <0.01
Slovenian: * vrednost p < 0,0001 ** vrednost p < 0,001
English: The overall frequency of urinary tract infection reported as adverse event was higher in patients treated with empagliflozin 10 mg on a background of metformin compared to patients treated with placebo or empagliflozin 25 mg on a background of metformin (see section 4.8).
Slovenian: Skupna pogostnost okužb sečil, o kateri so poročali kot o neželenem učinku, je bila pri bolnikih, zdravljenih z empagliflozinom 10 mg, večja v primerjavi z bolniki, ki so prejemali placebo ali empagliflozin 25 mg, pri čemer sta obe skupini zdravila prejemali skupaj z metforminom (glejte poglavje 4.8).
English: The risk of lactic acidosis must be considered in the event of non-specific signs such as muscle cramps, digestive disorders as abdominal pain and severe asthenia.
Slovenian: Na možnost laktacidoze je treba premisliti, če se pojavijo nespecifični znaki, kot so mišični krči, prebavne motnje, kot so trebušne bolečine, in huda astenija.
English: Table 2: Efficacy results of 24 week placebo-controlled studies Add-on to metformin therapya
Slovenian: Preglednica 2: Rezultati učinkovitosti 24-tedenskih s placebom nadzorovanih študij Dodatno zdravljenje k metforminua placebo empagliflozin
English: 2 not evaluated for statistical significance as a part of the sequential confirmatory testing procedure 3 Week 19-40: treat-to-target regimen for insulin dose adjustment to achieve pre-defined glucose target levels (pre-prandial <100 mg/dl (5.5 mmol/l), post-prandial <140 mg/dl (7.8 mmol/l) * p-value ≤0.0005
Slovenian: 3 19.-40. teden: usmerjen (treat-to-target) režim prilagajanja odmerka insulina za doseganje vnaprej določenih ciljnih ravni glukoze (preprandialna < 100 mg/dl (5,5 mmol/l), postprandialna < 140 mg/dl (7,8 mmol/l)
English: What you need to know before you take Synjardy
Slovenian: Kaj morate vedeti, preden boste vzeli zdravilo Synjardy Ne jemljite zdravila Synjardy:
English: • burning sensation when passing urine
Slovenian: • pekoč občutek pri uriniranju • moten urin
English: Overall hypoglycaemia
Slovenian: Skupna hipoglikemija
English: The active substances are empagliflozin and metformin.
Slovenian: Zdravilni učinkovini sta empagliflozin in metformin.
English: The overall frequency of urinary tract infection adverse events was higher in metformin-treated patients who received empagliflozin 10 mg (8.8%) compared to empagliflozin 25 mg (6.6%) or placebo (7.8%).
Slovenian: zdravljenih z metforminom, ki so prejemali empagliflozin 10 mg (8,8 %), višja kot pri bolnikih, ki so prejemali empagliflozin 25 mg (6,6 %) ali placebu (7,8 %).
English: Glimepirideb
Slovenian: Laktacidoza
English: Therefore, this medicinal product must be discontinued prior to, or at the time of the test and not reinstituted until 48 hours afterwards, and only after renal function has been re-evaluated and has not deteriorated further (see section 4.4).
Slovenian: Ponovno se ga sme uvesti šele po 48 urah in ponovni oceni delovanja ledvic, če se to ni dodatno poslabšalo (glejte poglavje 4.4).
English: Multiple-dose study: After repeated doses of 500 mg twice daily for 7 days in paediatric patients the peak plasma concentration (Cmax) and systemic exposure (AUC0-t) were approximately 33% and 40% lower, respectively, compared to diabetic adults who received repeated doses of 500 mg twice daily for 14 days.
Slovenian: Študija z večkratnimi odmerki: Po ponavljajočih odmerkih 500 mg, ki so jih dvakrat dnevno 7 dni prejemali pediatrični bolniki, sta bili pri njih največja koncentracija v plazmi (Cmax) za približno 33 %
English: Placebo empagliflozin
Slovenian: Empagliflozin Absorpcija
English: Add-on to metformin and a sulphonylurea therapya Placebo
Slovenian: Dodatno zdravljenje k metforminu s sulfonilsečninoa placebo empagliflozin
English: Treatment with iodinated contrast agent can reduce your kidney function and increase the risk of side effects due to the metformin component.
Slovenian: Izpostavljenost jodiranim kontrastnim sredstvom lahko poslabša delovanje ledvic in poveča tveganje neželenih učinkov zaradi metformina.
English: The steady state mean plasma AUC and Cmax were 1870 nmol.h and 259 nmol/l with empagliflozin 10 mg and 4740 nmol.h and 687 nmol/l with empagliflozin 25 mg once daily.
Slovenian: enkratno dnevno uporabo empagliflozina so bile v stanju dinamičnega ravnovesja vrednosti v plazmi AUC 1.870 nmol.h in Cmax 259 nmol/l za empagliflozin 10 mg ter AUC 4.740 nmol.h in
English: Due to the metformin component, Synjardy may cause a very rare, but very serious complication called lactic acidosis, particularly if your kidneys are not working properly.
Slovenian: Zaradi metformina lahko zdravilo Synjardy zlasti pri osebah z okvarjenim delovanjem ledvic povzroči zelo redek in resen zaplet, imenovan laktacidoza.
English: An increased frequency was noted when empagliflozin given as add-on to metformin and a sulfonylurea (empagliflozin 10 mg: 16.1%, empagliflozin 25 mg: 11.5% and placebo: 8.4%) or as add-on to metformin and insulin (empagliflozin 10 mg: 31.3%, empagliflozin 25 mg: 36.2% and placebo: 34.7%).
Slovenian: 25 mg: 11,5 %, placebo: 8,4 %) ali kot dodatnega zdravljenja k metforminu in insulinu (empagliflozin 10 mg: 31,3 %, empagliflozin 25 mg: 36,2 % in placebo: 34,7 %).
English: Administration of iodinated contrast agent
Slovenian: Uporaba jodiranega kontrastnega sredstva
English: Empagliflozin does not inhibit human uptake transporters such as OAT3, OATP1B1, and OATP1B3 in vitro at clinically relevant plasma concentrations and, as such, drug-drug interactions with substrates of these uptake transporters are considered unlikely.
Slovenian: OATP1B3 v klinično pomembnih plazemskih koncentracijah, zato medsebojno delovanje zdravila s substrati teh privzemnih prenašalcev ni verjetno.
English: Major hypoglycaemia (hypoglycaemia requiring assistance) The frequency of patients with major hypoglycaemic events was low (<1%) and similar for empagliflozin and placebo as add-on to metformin.
Slovenian: Pogostnost bolnikov s hudimi hipoglikemičnimi dogodki je bila nizka (< 1 %) in podobna za empagliflozin in placebo kot dodatno zdravljenje k metforminu.
English: The dosage should be individualised on the basis of the patient's current regimen, effectiveness, and tolerability using the recommended daily dose of 10 mg or 25 mg of empagliflozin, while not exceeding maximum recommended daily dose of metformin.
Slovenian: Uporabljati je potrebno priporočeni dnevni odmerek empagliflozina po 10 mg ali 25 mg, ne da bi pri tem presegli največji priporočeni dnevni odmerek metformina.
English: Therefore, this medicinal product must be discontinued prior to, or at the time of the test and not be reinstituted until at least 48 hours afterwards, and only after renal function has been re-evaluated and has not deteriorated further (see section 4.5).
Slovenian: Ponovno se ga sme uvesti šele po 48 urah in ponovni oceni delovanja ledvic, če se to ni dodatno poslabšalo (glejte poglavje 4.5).
English: • iodinated contrast agents (medicines used during an X-ray, see section 2 ‘Warnings and precautions'.
Slovenian: • jodirana kontrastna sredstva (ki jih lahko prejmete pri rentgenskem slikanju, glejte poglavje 2
English: The most commonly reported adverse events in clinical trials were hypoglycaemia in combination with insulin and/or sulphonylurea, urinary tract infections,
Slovenian: Najpogostejši neželeni učinki, o katerih so poročali v kliničnih preskušanjih, so bili hipoglikemija (pri kombinaciji z insulinom in/ali sulfonilsečnino), okužba sečil, okužba spolovil in pogostejše uriniranje (glejte opis izbranih neželenih učinkov).
English: Table 3: Efficacy results at 104 week in an active controlled study comparing empagliflozin to glimepiride as add on to metformina
Slovenian: Preglednica 3: Rezultati učinkovitosti v 104. tednu v z zdravilno učinkovino nadzorovani študiji, v kateri so empagliflozin primerjali z glimepiridom kot dodatnim zdravljenjem k metforminua empagliflozin 25 mg glimepiridb
English: Volume depletion1, 2
Slovenian: Žilne bolezni zmanjšanje volumna1, 2
English: At Week 52, treatment with empagliflozin resulted in a statistically significant decrease in HbA1c and insulin sparing compared with placebo and a reduction in body weight.
Slovenian: HbA1c, varčevanje z insulinom v primerjavi s placebom in zmanjšanje telesne mase.
English: • redness of the skin (erythema) or an itchy rash (hives)
Slovenian: • pordelost kože (eritem) ali srbeč izpuščaj (koprivnica) Poročanje o neželenih učinkih
English: Add-on to pioglitazone + metformin therapyb Placebo
Slovenian: Dodatno zdravljenje k pioglitazonu z metforminomb placebo empagliflozin
English: Urinary tract infection1, 2
Slovenian: okužbe sečil1, 2
English: An interaction study with gemfibrozil, an in vitro inhibitor of OAT3 and OATP1B1/1B3 transporters, showed that empagliflozin Cmax increased by 15% and AUC increased by 59% following co-administration.
Slovenian: OATP1B1/1B3, je pokazala, da se je po sočasni uporabi Cmax empagliflozina povečal za 15 %, AUC pa za 59 %.
English: 4 Mean adjusted for baseline SBP, baseline HbA1c, baseline eGFR, geographical region and number of antihypertensive medicinal products 5 Mean adjusted for baseline DBP, baseline HbA1c, baseline eGFR, geographical region and number of antihypertensive medicinal products * p-value <0.0001
Slovenian: 4 Povprečje, prilagojeno za vrednost sistoličnega krvnega tlaka ob izhodišču, vrednost HbA1c ob izhodišču, vrednost eGFR ob izhodišču, geografsko regijo in število antihipertenzivnih zdravil 5 Povprečje, prilagojeno za vrednost diastoličnega krvnega tlaka ob izhodišču, vrednost HbA1c ob izhodišču, vrednost eGFR ob izhodišču, geografsko regijo in število antihipertenzivnih zdravil
English: The onset of lactic acidosis can be subtle and the symptoms can be non-specific such as vomiting, bellyache (abdominal pain) with muscle cramps, a general feeling of not being well with severe tiredness, and difficulty in breathing.
Slovenian: Nastop laktacidoze je lahko skoraj nezaznaven z nespecifičnimi simptomi, kot so bruhanje, trebušne bolečine z mišičnimi krči, splošno slabo počutje z izrazito utrujenostjo in oteženo dihanje.
English: Synjardy 12.5 mg/850 mg and Synjardy 12.5 mg/1,000 mg tablets also contain iron oxide black (E172) and iron oxide red (E172).
Slovenian: 12,5 mg/1000 mg tablete vsebujejo tudi črni (E172) in rdeči železov oksid (E172).
English: 2 Not evaluated for statistical significance as a part of the sequential confirmatory testing procedure 3 LOCF, values after antihypertensive rescue censored
Slovenian: 1 Povprečje, prilagojeno za izhodiščne vrednosti 2 Statistična značilnost ni bila ocenjena zaradi zaporednega potrditvenega postopka testiranja
English: N HbA1c (%) at week 52b
Slovenian: Vrednost HbA1c (%) v 52. tednub
English: N HbA1c (%) at week 18a
Slovenian: N Vrednost HbA1c (%) v 18. tednua
English: Synjardy 12.5 mg/1,000 mg film-coated tablets
Slovenian: Synjardy 12,5 mg/1000 mg filmsko obložene tablete
English: ** p-value <0.001
Slovenian: * vrednost p < 0,0001
English: Increased urination1, 2
Slovenian: Bolezni sečil pogostejše uriniranje1, 2
English: Following administration of a dose of 850 mg metformin hydrochloride, a 40% lower plasma peak concentration, a 25% decrease in AUC and a 35 minute prolongation of the time to peak plasma concentration were observed.
Slovenian: Po dajanju odmerka metforminijevega klorida 850 mg so izmerili za 40 % manjšo največjo koncentracijo v plazmi, za
English: Nervous system disorders
Slovenian: Bolezni živčevja motnje okušanja3
English: 10 mg or 25 mg as add-on to metformin resulted in statistically significant reductions in HbA1c at Week 24 (adjusted mean change from baseline of -1.49% for empagliflozin 25 mg, -1.40% for empagliflozin 10 mg, and -0.44% for placebo).
Slovenian: V predhodno specificirani analizi bolnikov z izhodiščno vrednostjo HbA1c ≥ 9,0 % je zdravljenje z empagliflozinom 10 mg ali 25 mg kot dodatno zdravljenje k metforminu povzročilo statistično pomembno zmanjšanje vrednosti HbA1c v 24. tednu (prilagojena povprečna sprememba od izhodišča: -1,49 % za empagliflozin 25 mg, -1,40 % za empagliflozin 10 mg in -0,44 % za placebo).
English: Difference from glimepiride1 (97.5% CI) a Full analysis set (FAS) using last observation carried forward (LOCF) prior to glycaemic rescue therapy b Up to 4 mg glimepiride
Slovenian: IZ) a Niz celotne analize (FAS, full analysis set) z uporabo zadnjega opazovanja prenesenega naprej (LOCF, last observation carried forward) pred uporabo reševalnega zdravljenja za ureditev glikemije b Do 4 mg glimepirida
English: Your kidneys will be tested by a blood test before you start taking and while you are taking this medicine.
Slovenian: Pred začetkom jemanja ali med jemanjem tega zdravila boste morali opraviti krvne preiskave za preverjanje delovanja ledvic.
English: ** p-value <0.005
Slovenian: * vrednost p ≤ 0,0005
English: Patients (%) achieving HbA1c <7% with baseline HbA1c ≥7%2
Slovenian: Bolniki (%) z izhodiščno vrednostjo HbA1c ≥ 7 %, ki so dosegli vrednost HbA1c N
English: Lactic acidosis.
Slovenian: Laktacidoza.
English: 2 Mean adjusted for baseline HbA1c, baseline eGFR, geographical region and number of antihypertensive medicinal products 3 LOCF, values after taking antidiabetic rescue therapy or changing antihypertensive rescue therapy censored
Slovenian: 1 LOCF, vrednosti po cenzuriranju uporabe antidiabetičnega reševalnega zdravljenja 2 Povprečje, prilagojeno za vrednost HbA1c ob izhodišču, vrednost eGFR ob izhodišču, geografsko regijo in število antihipertenzivnih zdravil
English: HbA1c of <7% compared to linagliptin 5 mg. Clinically meaningful reductions in HbA1c were maintained for 52 weeks.
Slovenian: Klinično pomembna znižanja vrednosti HbA1c so se ohranila 52 tednov.
English: (95% CI) a Full analysis set (FAS) using last observation carried forward (LOCF) prior to glycaemic rescue therapy bSubgroup analysis for patients on additional background of metformin (FAS, LOCF) 1 Mean adjusted for baseline value
Slovenian: Sprememba od izhodišča1 Razlika glede na placebo1 (95-odstotni IZ) a Niz celotne analize (FAS, full analysis set) z uporabo zadnjega opazovanja prenesenega naprej (LOCF, last observation carried forward) pred uporabo reševalnega zdravljenja za ureditev glikemije b Analiza pri podskupinah bolnikov ob prisotnosti metformina (FAS, LOCF)
English: Diuretics
Slovenian: Diuretiki
English: Change from baseline1
Slovenian: Sprememba od izhodišča5
English: Table 5 Efficacy results at 18 and 78 weeks in a placebo-controlled study of empagliflozin as add on to basal insulin with metformina
Slovenian: Preglednica 5: Rezultati učinkovitosti v 18. in 78. tednu v s placebom nadzorovani študiji empagliflozina kot dodatnega zdravljenja k bazalnemu insulinu z metforminoma placebo empagliflozin 10 mg empagliflozin 25 mg
English: Other side effects while taking Synjardy: Very common
Slovenian: Drugi neželeni učinki, ki se lahko pojavijo med jemanjem zdravila Synjardy:
English: Your blood sugar levels may increase when you stop taking Synjardy.
Slovenian: Synjardy prenehali jemati, se bodo ravni krvnega sladkorja morda povišale.
English: HbA1c <7% with baseline HbA1c ≥7% at week 52b, 2
Slovenian: Bolniki (%) z izhodiščno vrednostjo HbA1c ≥ 7 %, ki so dosegli vrednost HbA1c < 7 % v 52. tednub, 2
English: Similar results were obtained when Synjardy (empagliflozin/metformin) combination tablets were administered with high-fat and high calorie meal.
Slovenian: (empagliflozin/metmorfin) sočasno z obrokom z visoko vsebnostjo maščob in kalorij.
English: Effects of other medicinal products on empagliflozin In vitro data suggest that the primary route of metabolism of empagliflozin in humans is glucuronidation by uridine 5'-diphosphoglucuronosyltransferases UGT1A3, UGT1A8, UGT1A9, and UGT2B7.
Slovenian: Študije in vitro so pokazale, da je glavna presnovna pot empagliflozina pri človeku glukuronidacija z uridin 5‘-difosfo-glukuronoziltransferazami UGT2B7,
English: Interaction studies conducted in healthy volunteers suggest that the pharmacokinetics of empagliflozin were not influenced by co-dministration with metformin, glimepiride, pioglitazone, sitagliptin, linagliptin, warfarin, verapamil, ramipril, simvastatin, torasemide and hydrochlorothiazide.
Slovenian: glimepirida, pioglitazona, sitagliptina, linagliptina, varfarina, verapamila, ramiprila, simvastatina, torasemida in hidroklorotiazida ni vplivala na farmakokinetiko empagliflozina.
English: Insulin dose (IU/day)
Slovenian: Odmerek bazalnega insulina (i.e./dan) v 78. tednu
English: • loss of appetite
Slovenian: • izguba teka Pogosti
English: Empagliflozin 25 mg
Slovenian: povezani z odmerkom 25 mg.
English: 4.7 Effects on ability to drive and use machines
Slovenian: 4.7 Vpliv na sposobnost vožnje in upravljanja s stroji Zdravilo Synjardy ima blag vpliv na sposobnost vožnje in upravljanja s stroji.